(RTTNews) – Moderna Inc. (MRNA) said Monday that the first participant has been dosed in the phase 1 study of mRNA-6231, the company’s mRNA-encoded IL-2 modified for the expansion of regulatory T cells.
mRNA-6231 is Moderna‘s autoimmune candidate to enter the clinic. It is also the company’s first subcutaneously administered therapeutic program.
Moderna now has active clinic programs in five different therapeutic areas: infectious disease, oncology, cardiovascular, rare disease and autoimmune disease.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.